Novo Nordisk, Eli Lilly slide after Trump comments on weight loss drug pricing
Brandon O'Brien, the Chief Financial Officer of CorVel Corp (NASDAQ:CRVL), recently executed a series of stock sales totaling $182,097, according to a filing with the Securities and Exchange Commission. The transactions, which took place on February 11, 2025, involved the sale of 1,523 shares of common stock at a price of $119.565 per share. The sale comes as CorVel trades near its 52-week high of $128.61, with the stock delivering an impressive 47% return over the past year.
Following these transactions, O'Brien's direct ownership of CorVel stock stands at 17,142 shares. The sales were conducted as part of routine financial management, with no indications of any broader strategic shifts. According to InvestingPro data, CorVel maintains a strong financial health score of 3.18 (rated as "GREAT"), with robust profitability metrics including a 22.4% gross margin.
Investors often keep a close eye on insider transactions like these, as they can provide insights into the executive's confidence in the company's future performance. However, it's important to note that insider sales can occur for a variety of personal financial reasons and do not necessarily reflect the executive's outlook on the company's prospects. InvestingPro subscribers can access 10+ additional key insights about CorVel's valuation and financial health through the comprehensive Pro Research Report, helping investors make more informed decisions about the company's current market position.
In other recent news, CorVel Corporation has reported an impressive performance in the fourth quarter of 2024. The company's earnings per share (EPS) saw a substantial increase of 39%, reaching $0.46, while revenues climbed to $228 million, a 13% year-over-year rise. The company attributes these results to ongoing investments in AI and automation within healthcare services.
CorVel also completed a 3-for-1 stock split in December 2024. Analysts have noted that the company's EPS and revenue figures exceeded market expectations. The company's unique development team and proprietary CareMC system are seen as key factors in maintaining its competitive edge.
Looking ahead, CorVel is committed to expanding its AI and automation capabilities, with projected EPS for FY2025 and FY2026 set at $1.76 and $1.82, respectively. Revenue estimates for the same periods stand at $854.96 million and $884.88 million. These recent developments underscore CorVel's commitment to technological innovation and financial growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.